First-in-Human Trial of VBC106 in Participants With Advanced Solid Tumors

Phase 1/2a Open-Label Clinical Trial Evaluating VBC106, an FRα- and MSLN-Directed Bispecific Antibody Drug Conjugate, in Participants With Advanced Malignant Solid Tumors

This is a multicenter, open-label, multiple-dose, FIH Phase 1/2a trial. The Phase 1 portion adopts BOIN design to identify the MTD and/or RP2D with potential backfill cohorts. The Phase 2a portion consists of dose optimization followed by cohort expansion to confirm safety and tolerability and to further evaluate the efficacy of the selected RP2D in selected solid tumor malignancies for VBC106.

Inclusion Criteria:

• - A participant must meet all of the following inclusion criteria to be eligible to participate in this trial:
• 1. The participant or the participant's legally acceptable representative is willing and able to provide a written ICF before initiating any trial procedure.
• 2. Histologically or cytologically confirmed unresectable advanced/metastatic solid tumor that has relapsed or progressed on or after standard systemic treatments, or is intolerable with standard treatment, or standard therapies are not appropriate or not safe in the opinion of the Investigator or refused by the participant.
• 3. At least one measurable lesion as assessed according to RECIST v1.1 criteria for participants with non-pleural mesothelioma or other solid tumors and modified RECIST(mRECIST) for participants with malignant pleural mesothelioma.
• 4. Male or female adults (defined as ≥ 18 years of age)
• 5. ECOG performance status 0-1
• 6. Has LVEF ≥ 50% by either ECHO or MUGA within 28 days before enrollment.
• 7. Life expectancy greater than 12 weeks
• 8. Archived tumor tissue sample available or able to undergo a fresh biopsy collection.
• 9. Adequate organ and bone marrow function

Exclusion Criteria:

1. Any unresolved toxicity of Grade ≥2 from previous anti-cancer treatment.
2. Known or suspected brain metastases, or spinal cord compression.
3. Has a medical history of interstitial lung diseases (e.g., non-infectious interstitial pneumonia, pneumonitis, pulmonary fibrosis, and severe radiation pneumonitis) or current interstitial lung diseases or who are suspected to have these diseases by imaging at screening.
4. Has a history of underlying pulmonary disorder including.
5. History of chronic, active, or hereditary corneal disease.
6. Participant history of congestive heart failure (CHF) Class II-IV according to the New York Heart Association (NYHA) Functional Classification or serious cardiac arrhythmias requiring treatment.